Arrowhead Phamaceuticals’ plozarsiran and zodasiran hold potential to treat dyslipidemia

By Isabel Cameron

- Last updated on GMT

© Getty Images
© Getty Images

Related tags Heart cardiovascular disease Fda Clinical trials

At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the phase 2 clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3).

The phase 2 SHASTA-2 study showed that plozasiran decreased APOC3 to -79%, triglycerides (TGs) to -74%, remnant cholesterol to -65% and increased high-density lipoprotein (HDL)-cholesterol (HDL-C) to 68% at 24 weeks in patients with severe hypertriglyceridemia.

In the phase 2 ARCHES-2 study, zodasiran showed reductions of ANGPTL3 up to -71% at week 8, TGs up to 59% at week 16, and low-density lipoprotein (LDL)-C up to -32% at week 16 in patients with mixed dyslipidemia.

The results show that plozarsiran and zodasiran hold potential to treat dyslipidemia, says data and analytics company GlobalData.

According to GlobalData’s analyst consensus sales forecast, plozasiran is expected to reach sales of $651 million by 2030, while zodasiran is expected to reach sales of $399 million by 2029.

Dr Shireen Mohammad, cardiovascular and metabolic disorders analyst at GlobalData, comments: “Plozasiran is an antisense oligonucleotide (ASO) and zodasiran is a small interfering RNA (siRNA). They are both RNA-based therapies that target specific genes involved in lipid metabolism, such as angiopoietin-like protein 3 (ANGPTL3) and apolipoprotein C3 (APOC3). ANGPTL3 is a protein that regulates lipid metabolism, and inhibiting this protein has been shown to reduce TG levels.”

Zodasiran is being investigated for the treatment of homozygous familial hypercholesterolemia (HoFH), with plans for phase 3 clinical trials.

ARO-ANG3 is forecast to launch in 2026. In March 2023, Arrowhead Pharmaceuticals announced that the FDA had granted fast track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS).

ARO-APOC3 is currently being investigated in a phase 3 clinical study in patients with FCS and is forecast to launch in 2026.

According to key opinion leaders interviewed by GlobalData, there is an unmet need for drugs that treat severe genetic disorders, including FCS and familial hypercholesterolemia (FH).

Currently, there are no FDA-approved therapies to treat FCS. Therefore, there is a critical unmet need for new FCS treatments that effectively lower triglyceride levels and prevent the complications associated with this disease.

Dr Mohammad concludes: “If approved, plozasiran and zodasiran will offer hope to dyslipidemia patients. However, drug developers will need to carefully consider how they price their medications and which patients they will initially target in order to successfully penetrate the market.”

Related topics Bio Developments Emerging Markets

Related news

Show more